Surgical implantation of steroids with antiangiogenic characteristics for treating neovascular age-related macular degeneration

Cochrane Database of Systematic Reviews

Volumn 2013, Issue 1, 2013, Pages

  Geltzer, Arthur ^a   Turalba, Angela ^b   Vedula, Satyanarayana S ^c  

^a BROWN UNIVERSITY   (United States)

^b MASSACHUSETTS EYE AND EAR INFIRMARY   (United States)

^c JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANECORTAVE; PLACEBO; STEROID; TRIAMCINOLONE ACETONIDE; ANGIOGENESIS INHIBITOR; PREGNANE DERIVATIVE;

ANTIANGIOGENIC ACTIVITY; DRUG EFFECT; EVIDENCE BASED MEDICINE; FOLLOW UP; HUMAN; PHOTODYNAMIC THERAPY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SYSTEMATIC REVIEW; WET MACULAR DEGENERATION; DRUG IMPLANT; PHOTOCHEMOTHERAPY; RETINA MACULA DEGENERATION; SUBRETINAL NEOVASCULARIZATION;

ANGIOGENESIS INHIBITORS; CHOROIDAL NEOVASCULARIZATION; DRUG IMPLANTS; HUMANS; MACULAR DEGENERATION; PHOTOCHEMOTHERAPY; PREGNADIENEDIOLS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TRIAMCINOLONE ACETONIDE;

MLCS; MLOWN;

EID: 84874802818     PISSN: None     EISSN: 1469493X     Source Type: Journal    
DOI: 10.1002/14651858.CD005022.pub3     Document Type: Review

References (49)

1. Augustin AJ, D'Amico DJ, Mieler WF, Schneebaum C, Beasley C. Safety of posterior juxtascleral depot administration of the angiostatic cortisone anecortave acetate for treatment of subfoveal choroidal neovascularization in patients with age-related macular degeneration. Graefe's Archive for Clinical and Experimental Ophthalmology 2005;243(1):9-12.
2. Regillo CD, D'Amico DJ, Mieler WF, Beasley CH, Schneebaum C. Safety of anecortave acetate administered as posterior juxtascleral injection in patients with subfoveal choroidal neovascularization. American Academy of Ophthalmology. 2002:282.
3. Schmidt-Erfurth U, Michels S, Michels R, Aue A. Anecortave acetate for the treatment of subfoveal choroidal neovascularization secondary to age-related macular degeneration. European Journal of Ophthalmology 2005;15(4):482-5.
4. The Anecortave Acetate Clinical Study Group. Anecortave acetate as monotherapy for the treatment of subfoveal lesions in patients with exudative age-related macular degeneration (AMD) - Interim (month 6) analysis of clinical safety and efficacy. Retina 2003;23(1):14-23.
5. The Anecortave Acetate Clinical Study Group. Anecortave acetate as monotherapy for treatment of subfoveal neovascularization in age-related macular degeneration - twelve-month clinical outcomes. Ophthalmology 2003;110(12):2372-83.
6. Gillies MC, Simpson JM, Billson FA, Luo W, Penfold P, Chua W, et al.Safety of an intravitreal injection of triamcinolone. Results from a randomized clinical trial. Archives of Ophthalmology 2004;122(3):336-40.
7. Gillies MC, Simpson JM, Luo W, Penfold P, Hunyor ABL, Chua W, et al.A randomized clinical trial of a single dose of intravitreal triamcinolone acetonide for neovascular age-related macular degeneration. One-year results. Archives of Ophthalmology 2003;121(5):667-73.
8. Slakter JS, Bochow T, D'Amico DJ, Marks B, Jerdan J, Sullivan EK, et al.Anecortave acetate (15 milligrams) versus photodynamic therapy for treatment of subfoveal neovascularization in age-related macular degeneration. Ophthalmology 2006;113(1):3-13.
9. Arevalo JF, Mendoza AJ, Fernandez CF. Indocyanine green-mediated photothrombosis with and without intravitreal triamcinolone acetonide for subfoveal choroidal neovascularization in age-related macular degeneration: a pilot study. Retina 2005;25(6):719-26.
10. Agurto Rivera R, Diaz Rubio J, Torres Bernal L, Macky TA, Colina Luquez J, Papa Oliva G, et al.Intravitreal triamcinolone with transpupillary therapy for subfoveal choroidal neovascularization in age related macular degeneration. A randomized controlled pilot study [ISRCTN74123635]. BMC Ophthalmology 2005;5:27.
11. Bakri SJ, Kaiser PK. Anercortave Acetate. Expert Opinion on Investigational Drugs 2006;15(2):163-9.
12. Challa JK, Gillies MC, Penfold PL, Gyory JF, Hunyor AB, Billson FA. Exudative macular degeneration and intravitreal triamcinolone: 18 month follow up. Australia New Zealand Journal of Ophthalmology 1998;26(4):277-81.
13. Danis RP, Ciulla TA, Pratt LM, Anliker W. Intravitreal triamcinolone acetonide in exudative age-related macular degeneration. Retina 2000;20(3):244-50.
14. EudraCT 2004-004857-24. Protocol A4321001: A phase 1/2, randomized, masked, single and multiple-dose, sequential dose-escalation study of the safety and efficacy of AG-013958 in subjects with subfoveal choroidal neovascularization associated with age-related macular degeneration. www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2004-004857-24 (accessed 21 October 2012).
15. Jonas JB, Kreissig I, Hugger P, Sauder G, Panda-Jonas S, Degenring R. Intravitreal triamcinolone acetonide for exudative age related macular degeneration. British Journal of Ophthalmology 2003;87(4):462-8.
16. Jonas JB, Akkoyun I, Budde WM, Kreissig I, Degenring RF. Intravitreal reinjection of triamcinolone for exudative age-related macular degeneration. Archives of Ophthalmology 2004;122(2):218-22.
17. Penfold PL, Gyory JF, Hunyor AB, Billson FA. Exudative macular degeneration and intravitreal triamcinolone. A pilot study. Australia New Zealand Journal of Ophthalmology 1995;23(4):293-8.
18. Ranson NT, Danis RP, Ciulla TA, Pratt L. Intravitreal triamcinolone in subfoveal recurrence of choroidal neovascularisation after laser treatment in macular degeneration. British Journal of Ophthalmology 2002;86(5):527-9.
19. Spaide RF, Sorenson J, Maranan L. Combined photodynamic therapy with verteporfin and intravitreal triamcinolone acetonide for choroidal neovascularization. Ophthalmology 2003;110(8):1517-25.
20. NRR Pub ID N0503172670 (03428). The safety and efficacy of posterior juxta-scleral (40 mg) or intra-vitreal (4 mg) triamcinolone acetonide, in addition to verteporfin photodynamic therapy for choroidal neovascularization (CNV), in age-related macular degeneration (AMD): a randomised controlled trial. www.controlled-trials.com/isrctn81615611 (accessed 21 October 2012).
21. Van De Moere A, Sandhu SS, Kak R, Mitchell KW, Talks SJ. Effect of posterior juxtascleral triamcinolone acetonide on choroidal neovascular growth after photodynamic therapy with verteporfin. Ophthalmology 2005;112(11):1896-1903.
22. Arias L, Garcia-Arumi J, Ramon J, Badia M, Rubio M, Pujol O. Optical coherence tomography analysis of a randomized study combining photodynamic therapy with intravitreal triamcinolone. Graefe's Archive for Clinical and Experimental Ophthalmology 2008;246(2):245-54.
23. BenEzra D, Griffin BW, Maftzir G, Sharif NA, Clark AF. Topical formulations of novel angiostatic steroids inhibit rabbit corneal neovascularization. Investigative Ophthalmology and Visual Science 1997;38(10):1954-62.
24. Blei F, Wilson EL, Mignatti P, Rifkin DB. Mechanism of action of angiostatic steroids: suppression of plasminogen activator activity via stimulation of plasminogen activator inhibitor synthesis. Journal of Cellular Physiology 1993;155(3):568-78.
25. Bressler NM, Treatment of Age-Related Macular Degeneration with Photodynamic Therapy (TAP) Study Group. Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporforin: two-year results of 2 randomized clinical trials - TAP report 2. Archives of Ophthalmology 2001;119(2):198-207.
26. Clark AF, Mellon J, Li XY, Ma D, Leher H, Apte R, et al.Inhibition of intraocular tumor growth by topical application of the angiostatic steroid anecortave acetate. Investigative Ophthalmology and Visual Science 1999;40(9):2158-62.
27. Evans JR. Risk factors for age-related macular degeneration. Progress in Retinal and Eye Research 2001;20(2):227-53.
28. Evans JR, Sivagnanavel V, Chong V. Radiotherapy for neovascular age-related macular degeneration. Cochrane Database of Systematic Reviews 2010, Issue 5. [DOI: 10.1002/14651858.CD004004.pub3]
29. Evans JR, Lawrenson JG. Antioxidant vitamin and mineral supplements for slowing the progression of age-related macular degeneration. Cochrane Database of Systematic Reviews 2012, Issue 6. [DOI: 10.1002/14651858.CD000254.pub2]
30. Evans JR. Ginkgo Biloba extract for age-related macular degeneration. Cochrane Database of Systematic Reviews 2013, Issue 1.
31. Ferris FL 3rd, Fine SL, Hyman L. Age-related macular degeneration and blindness due to neovascular maculopathy. Archives of Ophthalmology 1984;102(11):1640-2.
32. Glanville JM, Lefebvre C, Miles JN, Camosso-Stefinovic J. How to identify randomized controlled trials in MEDLINE: ten years on. Journal of the Medical Library Association 2006;94(2):130-6.
33. Higgins JPT, Altman DG, Sterne, JAC (editors). Chapter 8: Assessing risk of bias in included studies. In: Higgins JPT, Green S (editors). In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.
34. Klein R, Klein BE, Tomany SC, Meuer SM, Huang G. Ten-year incidence and progression of age-related maculopathy: The Beaver Dam Eye Study. Ophthalmology 2002;109(10):1767-79.
35. Maberley D, Canadian Retinal Trials Group. Photodynamic therapy and intravitreal triamcinolone for neovascular age-related macular degeneration: a randomized clinical trial. Ophthalmology 2009;116(11):2149-57.
36. Macular Photocoagulation Study Group. Laser photocoagulation for juxtafoveal choroidal neovascularization: Five-year results from randomized clinical trials. Archives of Ophthalmology 1994;112(4):500-9.
37. Panel on Handling Missing Data in Clinical Trials, National Research Council. The Prevention and Treatment of Missing Data in Clinical Trials. Washington, D.C: The National Academies Press, 2010.
38. Penfold PL, Madigan MC, Gillies MC, Provis JM. Immunological and etiological aspects of macular degeneration. Progress in Retinal and Eye Research 2001;20(3):385-414.
39. Reddy U, Krzystolik M. Antiangiogenic therapy with interferon alfa for neovascular age-related macular degeneration. Cochrane Database of Systematic Reviews 2006, Issue 1. [DOI: 10.1002/14651858.CD005138.pub2]
40. The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). 5.1. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2011.
41. TAP Study Group. Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporforin: One-year results of 2 randomized clinical trials -TAP Report 1. Archives of Ophthalmology 1999;117(10):1329-45.
42. Tielsch JM, Friedman DS, Congdon N, Kempen J. Vision Problems in the U.S. Prevalence of adult vision impairment and age-related eye disease in America. Prevent Blindness America, 2002.
43. Tsuchiya D, Yamamoto T, Saito K, Yamashita H. Comparison of photodynamic therapy with verteporfin combined with posterior juxtascleral triamcinolone acetonide and photodynamic therapy alone for age-related macular degeneration. Investigative Ophthalmology and Visual Science 2008:ARVO E-abstract 270.
44. Vedula SS, Krzystolik M. Antiangiogenic therapy with anti-vascular endothelial growth factor modalities for neovascular age-related macular degeneration. Cochrane Database of Systematic Reviews 2008, Issue 2. [DOI: 10.1002/14651858.CD005139.pub2]
45. TAP and VIP Study Groups. Photodynamic therapy of subfoveal choroidal neovascularization with verteporfin: Fluorescein angiographic guidelines for evaluation and treatment - TAP and VIP report No. 2. Archives of Ophthalmology 2003;121(9):1253-68.
46. Virgili G, Bini A. Laser photocoagulation for neovascular age-related macular degeneration. Cochrane Database of Systematic Reviews 2007, Issue 3. [DOI: 10.1002/14651858.CD004763.pub2]
47. WHO. Fact sheet (1997). www.who.int/inf-fs/en/fact144.html (accessed April 2003).
48. Wormald R, Evans JR, Smeeth LL, Henshaw KS. Photodynamic therapy for neovascular age-related macular degeneration. Cochrane Database of Systematic Reviews 2007, Issue 3. [DOI: 10.1002/14651858.CD002030.pub2]
49. Geltzer A, Turalba A, Vedula SS. Surgical implantation of steroids with antiangiogenic characteristics for treating neovascular age-related macular degeneration. Cochrane Database of Systematic Reviews 2007, Issue 4. [DOI: 10.1002/14651858.CD005022.pub2]